image_pdfimage_print

Obesity portfolio roadmap beyond GLP-1 with preventive bariatric surgery

Life Sciences

Aug 20, 2025

1230 Views

2 min read

Add to Favourite

Quick Overview

A global pharma player needed to diversify its obesity portfolio beyond reliance on GLP-1 therapies. With intensifying competition, regulatory uncertainty, and the emergence of Preventive Bariatric Surgery as a complementary solution, the client sought a foresight-led roadmap to guide portfolio strategy, mitigate risks, and capture long-term growth opportunities. FutureBridge_Preventive Bariatric Surgery for a Global Pharma Player

Client Success Details

FutureBridge conducted a comprehensive foresight engagement integrating regulatory horizon scanning, competitive benchmarking, and clinical-commercial insights. The objective was to clarify regulatory shifts, assess adjacent opportunities including Preventive Bariatric Surgery, and provide the client with a clear investment pathway for obesity portfolio resilience.

The key questions addressed were:
  FutureBridge integrated foresight model blending payer interviews, regulatory horizon scans, and clinical-commercial evidence grading enabled a 360° view of obesity market adjacencies. This approach brought forward insights often missed in traditional pipeline assessments, particularly around Preventive Bariatric Surgery’s reimbursement trajectory and market scalability.
  • How will regulatory and reimbursement frameworks shape the adoption of GLP-1 therapies and Preventive Bariatric Surgery?
  • Which adjacent innovations offer scalable and clinically validated opportunities?
  • What market adjacencies can reduce long-term strategic and portfolio risk?
  • How should the client prioritize investments to balance compliance, innovation, and growth?
 
FutureBridge_Preventive Bariatric Surgery FutureBridge_Preventive Bariatric Surgery

FutureBridge_BMI parameters Preventive Bariatric Surgery

Engagement Framework:

  • Regulatory Horizon Scanning:
    Reviewed FDA, EMA, and APAC regulatory pathways for obesity therapies and surgical interventions.
  • Innovation & Competitive Benchmarking:
    Compared GLP-1 therapies with Preventive Bariatric Surgery, digital therapeutics, and nutraceuticals.
  • Commercial Insights:
    Modeled payer landscapes, clinical adoption rates, and patient demand trajectories.
  • Opportunity Prioritization & Roadmap:
    Delivered a phased roadmap integrating adjacencies and partnerships to de-risk obesity strategy.
 FutureBridge_ long-term obesity market investment strategy

FutureBridge Impact

  • Identified 3 adjacent opportunity spaces beyond GLP-1, including Preventive Bariatric Surgery

  • Shortlisted 2 strategic partnership opportunities in digital health

  • Delivered regulatory clarity across 5 major global markets

  • Enabled a board-level decision on long-term obesity market investment strategy

Business Value Delivered

Through this foresight-led collaboration, FutureBridge empowered the client to:

  • De-risk GLP-1 dependency with diversified, adjacent therapies
  • Accelerate investment decisions with evidence-backed, regulatory-aligned insights
  • Strengthen portfolio resilience across emerging obesity treatment paradigms
  • Shape executive strategy for long-term value creation in a complex market landscape
Let’s talk. With EMA’s GLP-1 reclassification and FDA updates on the horizon, now is the time to reassess your obesity strategy. Connect with FutureBridge to uncover adjacencies and build a resilient, forward-looking portfolio.

Need a thought partner?

Share your focus area or question to engage with our Analysts through the Business Objectives service.

Submit My Business Objective

Our Clients

Our long-standing clients include some of the worlds leading brands and forward-thinking corporations.

Terms of Use
Privacy Policy
Cookie Policy
  • © 2026 Cheers Interactive (India) Private Limited. All rights reserved. FutureBridge ® is a registered trademark of Cheers Interactive (India) Private Limited.